Clinical trials in Pisa – page 10

582 clinical trials in Pisa, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Pisa at a glance

582

clinical trials

Research sites4

Quick filters

582 trials in Pisa

Open in trial search

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Myasthenia gravis

Recruiting

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Imeroprubart
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:PRAX-628
Sponsor:Praxis Precision Medicines Inc.

Contact Research Centre

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:GHZ339
Sponsor:Novartis Pharma AG

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

InvestigationalNo placebo

Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:TYRA-300-B01
Sponsor:Tyra Biosciences Inc.

Contact Research Centre

Colorectal cancer

Recruiting

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Chronic hepatitis B

Recruiting

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:ALG-000184
Sponsor:Aligos Therapeutics Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pisa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Investigating innovative treatments for cardiac conditions and metabolic disorders, with studies focusing on TTR amyloidosis cardiomyopathy and chronic kidney disease management.

Heart Disease Therapeutics
Kidney Disease Management
Hypertension Control

Current trials evaluate novel compounds for improving patient outcomes in cardiac conditions and renal disorders.

02 Oncology Studies

Comprehensive research into various cancer types, including colorectal cancer, gastric cancer, and lung cancer, testing targeted therapies and innovative treatment combinations.

Metastatic Cancer Treatment
Targeted Therapy Development
Immunotherapy Research

Advanced clinical trials exploring breakthrough treatments for multiple cancer types.

03 Autoimmune & Inflammatory Conditions

Studies focusing on chronic inflammatory conditions including Sjögren's Syndrome, psoriatic arthritis, and hidradenitis suppurativa.

Inflammatory Disease Management
Autoimmune Treatment Innovation
Novel Therapeutic Approaches

Evaluating new therapeutic options for improving quality of life in patients with chronic inflammatory conditions.

04 Respiratory & Infectious Diseases

Research into respiratory conditions and infectious diseases, including studies on chronic rhinosinusitis and respiratory syncytial virus infections.

Respiratory Disease Treatment
Infection Management
Vaccine Development

Investigating new approaches to treat and prevent respiratory infections and related conditions.

Back to Italy All countries